It attracts T-regulatory cells allowing for some cancers to evade an immune response. However, in other cancers, such as melanoma, an increase in CCL17 is linked to an improved outcome.
This phenomenon attracts T-regulatory cells, allowing some cancers to exploit the immune system's weaknesses. Conversely, in certain cases, like melanoma, elevated levels of CCL17 are linked to better clinical results.